Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Ryan E. Fecteau; Bridget F. Koontz; Karen E. Hoffman; Susan Halabi; Lauren E. Howard; Monika Anand; Daniel J. George; Tian Zhang; William R. Berry; W. Robert Lee; Michael R. Harrison; Paul G. Corn; Andrew J. Armstrong

doi:10.1038/s41391-024-00811-5

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Ryan E. Fecteau, Bridget F. Koontz, Karen E. Hoffman, Susan Halabi, Lauren E. Howard, Monika Anand, Daniel J. George, Tian Zhang, William R. Berry, W. Robert Lee, Michael R. Harrison, Paul G. Corn, Andrew J. Armstrong

Research output: Contribution to journal › Article › peer-review

Abstract

Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

Original language	English (US)
Journal	Prostate Cancer and Prostatic Diseases
DOIs	https://doi.org/10.1038/s41391-024-00811-5
State	Accepted/In press - 2024

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

Access to Document

10.1038/s41391-024-00811-5

Cite this

Fecteau, R. E., Koontz, B. F., Hoffman, K. E., Halabi, S., Howard, L. E., Anand, M., George, D. J., Zhang, T., Berry, W. R., Lee, W. R., Harrison, M. R., Corn, P. G., & Armstrong, A. J. (Accepted/In press). Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00811-5

Fecteau, RE, Koontz, BF, Hoffman, KE, Halabi, S, Howard, LE, Anand, M, George, DJ, Zhang, T, Berry, WR, Lee, WR, Harrison, MR, Corn, PG & Armstrong, AJ 2024, 'Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer', Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00811-5

@article{50bed302dba44f2f8e9c693d13ebd92c,

title = "Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer",

abstract = "Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.",

author = "Fecteau, {Ryan E.} and Koontz, {Bridget F.} and Hoffman, {Karen E.} and Susan Halabi and Howard, {Lauren E.} and Monika Anand and George, {Daniel J.} and Tian Zhang and Berry, {William R.} and Lee, {W. Robert} and Harrison, {Michael R.} and Corn, {Paul G.} and Armstrong, {Andrew J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2024.",

year = "2024",

doi = "10.1038/s41391-024-00811-5",

language = "English (US)",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

AU - Fecteau, Ryan E.

AU - Koontz, Bridget F.

AU - Hoffman, Karen E.

AU - Halabi, Susan

AU - Howard, Lauren E.

AU - Anand, Monika

AU - George, Daniel J.

AU - Zhang, Tian

AU - Berry, William R.

AU - Lee, W. Robert

AU - Harrison, Michael R.

AU - Corn, Paul G.

AU - Armstrong, Andrew J.

PY - 2024

Y1 - 2024

N2 - Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

AB - Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85185512348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185512348&partnerID=8YFLogxK

U2 - 10.1038/s41391-024-00811-5

DO - 10.1038/s41391-024-00811-5

M3 - Article

C2 - 38388778

AN - SCOPUS:85185512348

SN - 1365-7852

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

ER -

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this